Notable prospective clinical trials using checkpoint blockade before or after allogeneic transplant
| Clinical trial . | Title . |
|---|---|
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse after Allogeneic Stem Cell Transplantation |
| NCT02985554 | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients with Hematologic Malignancies |
| NCT03286114 | Augmentation of the Graft vs Leukemia Effect via Checkpoint Blockade with Pembrolizumab |
| NCT02846376 | Single Agent and Combined Inhibition after Allogeneic Stem Cell Transplant (CPIT-002) |
| NCT03146468 | Nivolumab for Relapsed or Residual Haematologic Malignancies after Allogeneic Stem Cell Transplantation (NIVALLO) |
| NCT03200977 | Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Classical Hodgkin Lymphoma (CHL) Treated with Nivolumab |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant |
| NCT02603419 | Avelumab in Patients with Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) |
| Clinical trial . | Title . |
|---|---|
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse after Allogeneic Stem Cell Transplantation |
| NCT02985554 | Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients with Hematologic Malignancies |
| NCT03286114 | Augmentation of the Graft vs Leukemia Effect via Checkpoint Blockade with Pembrolizumab |
| NCT02846376 | Single Agent and Combined Inhibition after Allogeneic Stem Cell Transplant (CPIT-002) |
| NCT03146468 | Nivolumab for Relapsed or Residual Haematologic Malignancies after Allogeneic Stem Cell Transplantation (NIVALLO) |
| NCT03200977 | Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Classical Hodgkin Lymphoma (CHL) Treated with Nivolumab |
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies after Donor Stem Cell Transplant |
| NCT02603419 | Avelumab in Patients with Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) |